Literature DB >> 17053139

Signal transduction. Prelude to an anniversary for the RAS oncogene.

Julian Downward1.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 17053139     DOI： 10.1126/science.1134727

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  14 in total

1.  Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes.

Authors:  Christian P Kratz; Suthee Rapisuwon; Helen Reed; Henrik Hasle; Philip S Rosenberg
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-15       Impact factor: 3.908

2.  A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).

Authors:  Tianhong Li; Mengye Guo; William J Gradishar; Joseph A Sparano; Edith A Perez; Molin Wang; George W Sledge
Journal:  Breast Cancer Res Treat       Date:  2012-05-01       Impact factor: 4.872

3.  Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

Authors:  Stefanie Derer; Sven Berger; Martin Schlaeth; Tanja Schneider-Merck; Katja Klausz; Stefan Lohse; Marije B Overdijk; Michael Dechant; Christian Kellner; Iris Nagelmeier; Andreas H Scheel; Jeroen J Lammerts van Bueren; Jan G J van de Winkel; Paul W H I Parren; Matthias Peipp; Thomas Valerius
Journal:  Neoplasia       Date:  2012-03       Impact factor: 5.715

4.  Activated Kras alters epidermal homeostasis of mouse skin, resulting in redundant skin and defective hair cycling.

Authors:  Anandaroop Mukhopadhyay; Suguna R Krishnaswami; Benjamin D-Y Yu
Journal:  J Invest Dermatol       Date:  2010-10-14       Impact factor: 8.551

Review 5.  Mosaic RASopathies.

Authors:  Christian Hafner; Leopold Groesser
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

6.  Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome.

Authors:  Hailan Hu; Yi Qin; Genrieta Bochorishvili; Yinghua Zhu; Linda van Aelst; J Julius Zhu
Journal:  J Neurosci       Date:  2008-07-30       Impact factor: 6.167

7.  A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines.

Authors:  Piotr Jasinski; Brandon Welsh; Jorge Galvez; David Land; Pawel Zwolak; Lori Ghandi; Kaoru Terai; Arkadiusz Z Dudek
Journal:  Invest New Drugs       Date:  2007-10-24       Impact factor: 3.850

Review 8.  Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.

Authors:  Matthias Peipp; Michael Dechant; Thomas Valerius
Journal:  MAbs       Date:  2009-11-11       Impact factor: 5.857

9.  H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors.

Authors:  Doinita Serban; Jie Leng; David Cheresh
Journal:  Circ Res       Date:  2008-05-08       Impact factor: 17.367

10.  Data recovery and integration from public databases uncovers transformation-specific transcriptional downregulation of cAMP-PKA pathway-encoding genes.

Authors:  Chiara Balestrieri; Lilia Alberghina; Marco Vanoni; Ferdinando Chiaradonna
Journal:  BMC Bioinformatics       Date:  2009-10-15       Impact factor: 3.169
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.